Seeking Alpha

Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about...

Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about proposed regulation of prenatal screening tests likely overstates the case as the FDA "has missed its window to regulate the non-invasive prenatal testing market." Analyst Zarak Khurshid upgrades the stock to Outperform from Neutral and reiterates a price target of $5. Shares +3.4% premarket. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)